Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Elamipretide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Advisory Committee To Review Stealth's Elamipretide For Barth Syndrome
    FDA Advisory Committee To Review Stealth's Elamipretide For Barth Syndrome

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-elamipretide-for-barth-syndrome-treatment-302242393.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth
    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-completes-mid-cycle-review-meeting-on-elamipretide-for-the-treatment-of-barth-syndrome-302207846.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD
    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD

    05 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-first-patient-enrolled-in-global-phase-3-clinical-program-for-elamipretide-in-patients-with-dry-age-related-macular-degeneration-302164947.html

    PR NEWSWIRE
    05 Jun 2024
    Share Share
    Stealth Biotherapeutics' Barth Syndrome NDA Receives Priority Review Designation
    Stealth Biotherapeutics' Barth Syndrome NDA Receives Priority Review Designation

    07 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-barth-syndrome-nda-receives-priority-review-designation-302138192.html

    PR NEWSWIRE
    07 May 2024
    Share Share
    Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug
    Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

    09 Apr 2024

    // Zachary Brennan ENDPTS

    https://endpts.com/stealth-bio-gets-fda-adcomm-for-previously-rejected-ultra-rare-disease-drug/

    Zachary Brennan ENDPTS
    09 Apr 2024
    Share Share
    Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome
    Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome-302109608.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share